Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease

被引:30
|
作者
Puolanne, Anna-Maija [1 ]
Kolho, Kaija-Leena [2 ]
Alfthan, Henrik [3 ]
Ristimaki, Ari [4 ,5 ,6 ]
Mustonen, Harri [7 ,8 ]
Farkkila, Martti [1 ]
机构
[1] Helsinki Univ Hosp, Dept Med, Gastroenterol Clin, Haartmaninkatu 4,POB 340, Helsinki 00290, Finland
[2] Helsinki Univ Hosp, Childrens Hosp, Stenbackinkatu 11, Helsinki 00290, Finland
[3] Helsinki Univ Hosp, Dept Clin Chem, Haartmaninkatu 2, Helsinki 00290, Finland
[4] Univ Helsinki, Res Programs Unit, Pathol, Haartmaninkatu 3, FIN-00290 Helsinki, Finland
[5] Univ Helsinki, HUSLAB, Haartmaninkatu 3, FIN-00290 Helsinki, Finland
[6] Helsinki Univ Hosp, Haartmaninkatu 3, Helsinki 00290, Finland
[7] Univ Helsinki, Dept Surg, Biomed Helsinki, Haartmaninkatu 8, FIN-00290 Helsinki, Finland
[8] Helsinki Univ Hosp, Haartmaninkatu 8, Helsinki 00290, Finland
关键词
Inflammatory bowel disease; Fecal calprotectin; Symptom index; Rapid fecal calprotectin test; QUALITY-OF-LIFE; CROHNS-DISEASE; ULCERATIVE-COLITIS; SURROGATE MARKERS; ENDOSCOPIC SCORE; THERAPY; VALIDATION; REMISSION; DIAGNOSIS; IBD;
D O I
10.1007/s10620-017-4770-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Fecal calprotectin is a reliable surrogate marker for inflammatory activity in inflammatory bowel disease (IBD). For the noninvasive monitoring of the activity of colonic inflammation, we validated a symptom index suitable for ulcerative colitis and colonic Crohn's disease. By combining the symptom index with a rapid semi-quantitative calprotectin test, we constructed a new activity index based on the highest AUCs, using histological remission as a reference. We also evaluated the correlation of the patient-reported influence of the IBD in the daily life, measured by a VAS, with the inflammation activity. The disease activity of 72 patients with IBD of the colon was determined by endoscopic activity scores (SES-CD/UCEIS). The patients provided stool samples for determination of calprotectin and filled in a questionnaire about their symptoms during the last week. The results of the symptom index demonstrated a statistically significant correlation with the rapid calprotectin test, histological inflammation activity, and the VAS. No correlations were found between the VAS and calprotectin or the histological inflammation activity. The sensitivity of the combination index to detect active inflammation was slightly superior to fecal calprotectin alone. The new symptom index and the combination index are simple, noninvasive means for distinguishing remission from active inflammation in colonic IBD. With the VAS, we can pick up patients who need psychosocial support because of the disease burden, even if their IBD is in remission.
引用
收藏
页码:3123 / 3130
页数:8
相关论文
共 50 条
  • [41] Fecal Calprotectin in Pediatric Inflammatory Bowel Disease: A Systematic Review
    Kostakis, Ioannis D.
    Cholidou, Kyriaki G.
    Vaiopoulos, Aristeidis G.
    Vlachos, Ioannis S.
    Perrea, Despina
    Vaos, George
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (02) : 309 - 319
  • [42] Fecal Calprotectin in Pediatric Inflammatory Bowel Disease: A Systematic Review
    Ioannis D. Kostakis
    Kyriaki G. Cholidou
    Aristeidis G. Vaiopoulos
    Ioannis S. Vlachos
    Despina Perrea
    George Vaos
    Digestive Diseases and Sciences, 2013, 58 : 309 - 319
  • [43] The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease
    Suarez Ferrer, Cristina
    Abadia Barno, Marta
    Martin Arranz, Eduardo
    Jochems, Andrea
    Garcia Ramirez, Laura
    Poza Cordon, Joaquin
    Jaquotot Herranz, Marta
    Cerpa Arencibia, Alberto
    Martin Arranz, Maria Dolores
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (10) : 744 - 749
  • [44] The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease
    Kwapisz, Lukasz
    Gregor, Jamie
    Chande, Nilesh
    Yan, Brian
    Ponich, Terry
    Mosli, Mahmoud
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (08) : 846 - 850
  • [45] Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease
    Dolinsek, Jernej
    Riznik, Petra
    Sabath, Larisa
    Micetic-Turk, Dusanka
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (7-8) : 253 - 259
  • [46] A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis
    Eva Klingberg
    Hans Strid
    Arne Ståhl
    Anna Deminger
    Hans Carlsten
    Lena Öhman
    Helena Forsblad-d’Elia
    Arthritis Research & Therapy, 19
  • [47] Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization
    Fukunaga, Shuhei
    Kuwaki, Kotaro
    Mitsuyama, Keiichi
    Takedatsu, Hidetoshi
    Yoshioka, Shinichiro
    Yamasaki, Hiroshi
    Yamauchi, Ryosuke
    Mori, Atsushi
    Kakuma, Tatsuyuki
    Tsuruta, Osamu
    Torimura, Takuji
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 41 (01) : 107 - 118
  • [48] Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis
    Shi, Jin-Tong
    Chen, Nuo
    Xu, Jia
    Goyal, Hemant
    Wu, Zhi-Qi
    Zhang, Jie-Xin
    Xu, Hua-Guo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [49] The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases
    Knyazev, O. V.
    Kagramanova, A. V.
    Korneeva, I. A.
    Noskova, K. K.
    Belousov, S. V.
    Parfenov, A. I.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (04) : 53 - 61
  • [50] Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control
    van Rheenen, Patrick F.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (11) : 2018 - 2025